Loos, a professor at the University of Copenhagen and affiliated with a research center supported by the Novo Nordisk Foundation (the maker of Wegovy and Ozempic), noted, "The current model explains only 25% of the variability, and further research is needed to uncover the remaining 75%." However, she also expressed optimism, stating, "By combining genetic and clinical information, the era of personalized medicine, where we can select the best drug for each patient, may be upon us."
Tanaka T, Warner BM, Odani T, Ji Y, Mo YQ, Nakamura H, et al
There is no substance-use or alcohol-use screen
Whether its a post-Christmas or pre-Easter effect, chocolate became the primary snack choice for GLP-1 users during Q1 2025